What is IQVIA Holdings Inc. (IQV) DCF Fair Value and Intrinsic Value in 2026?

IQVIA Holdings Inc. (IQV) intrinsic value is calculated using conservative multi-stage Discounted Cash Flow (DCF) models, 5-year free cash flow trajectories, Graham Numbers, and owner earnings multiples. LocalAlpha tracks real-time margin of safety against live market prices.

What is IQVIA Holdings Inc.'s historical Return on Invested Capital (ROIC) and Moat Rating?

IQVIA Holdings Inc. operates in the Healthcare sector (Diagnostics & Research) with an economic moat rating of NARROW. LocalAlpha tracks 5-year audited quarterly ROIC, operating margin stability, and balance sheet solvency ratios.

What is IQVIA Holdings Inc.'s financial health rating and Piotroski F-Score?

IQVIA Holdings Inc.'s balance sheet quality is evaluated using the 9-point Piotroski F-Score, Altman Z-Score solvency model, debt-to-equity ratio, and quick/current liquidity coverage to guard against financial distress.

How does LocalAlpha monitor IQVIA Holdings Inc. (IQV) for quarterly SEC filing thesis breaks?

LocalAlpha audits IQVIA Holdings Inc.'s 10-K, 10-Q, and 8-K regulatory filings on SEC EDGAR within 15 minutes of release. If reported metrics breach an investor's custom ROIC floor, operating margin boundary, or qualitative risk criteria, an autonomous breach audit is dispatched immediately.

StocksIQV

IQV

IQVIA Holdings, Inc.Healthcare / Diagnostics & ResearchINTACT

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.

Share Price

$261.77

52W: $154.5 - $271.8

DCF Fair Value

$175.09

-49.5% Premium

Thesis Hub

P/E (TTM)

32.6x

ROIC

9.8%

Operating Margin

13%

FCF Yield

Debt / Equity

2.58x

Piotroski Score

7/9

Altman Z-Score

2.97

Market Cap

$43.1B

Price vs. Intrinsic Value Corridor

Overvalued vs DCF ($175.09)

Historical market price overlaid against conservative DCF Fair Value & Benjamin Graham Margin of Safety bands.

Period Return (1Y)

—()

Period Range

$— - $—

DCF Fair Value

$175.09

MOS Buy Target (-25%)

$131.32

Valuation Overlays: DCF Fair Value ($175.09) 25% MOS Buy Target ($131.32) Revised Graham ($134.70) Graham Number ($82.30)

2-Stage Discounted Cash Flow (DCF) Workbench

Conservative intrinsic value model based on owner cash generation over a 10-year investment horizon. Opens with LocalAlpha's baseline assumptions (matching the fair value shown above) — adjust any input to stress-test.

Current Market Price

$261.77

DCF Fair Value

$174.15

-50.3% Premium

Starting Free Cash Flow ($M)$2,150M

$100M$2,150M (Reported)$50,000M

Stage 1 Growth (Years 1-5)6.5%

-5%10% (Target)35%

Stage 2 Growth (Years 6-10)4.5%

0%5%20%

Discount Rate (WACC / Hurdle)9.0%

6%9% (Standard)15% (High Risk)

Terminal Perpetual Growth2.5%

1% (GDP Floor)2.5% (Inflation)4.0%

Net Debt ($M)$14,200M

-$100B CashBalance Sheet+$150B Debt

10-Yr PV of Cash Flows

$18.5B

PV of Terminal Value

$24.5B

Implied Enterprise Value

$42.9B

Implied Equity Value

$28.7B

Year	Yr 1	Yr 2	Yr 3	Yr 4	Yr 5	Yr 6	Yr 7	Yr 8	Yr 9	Yr 10
Projected FCF ($M)	$2,290	$2,439	$2,597	$2,766	$2,946	$3,078	$3,217	$3,362	$3,513	$3,671
Present Value (PV)	$2,101	$2,053	$2,005	$1,959	$1,914	$1,835	$1,760	$1,687	$1,617	$1,551

Benjamin Graham & Buffett Value Models

Classical deep value metrics based on asset backing, normalized earnings power, and owner cash yield.

Graham Number-218.1% Premium

$82.30

Calculated as √(22.5 × EPS × BVPS). The maximum theoretical price a defensive investor should pay based purely on asset book value and current earnings.

EPS: $8.03BVPS: $37.49

Revised Graham Formula-94.3% Premium

$134.70

Formula: V = (EPS × (8.5 + 2g) × 4.4) / Y where g is the conservative 7-10 yr growth rate and Y is AAA Bond Yield.

Growth Rate (g%)

Bond Yield (Y%)

Buffett Owner Earnings4.7% Yield

$12.38 / share

True distributable cash flow: Net Income + D&A - Maintenance CapEx. Reflects the cash Buffett would extract without hurting unit volume.

Total: $2.0BYield: 4.7%

Reverse DCF: Market Growth Expectation

MODEST BARRIER

5.7% CAGR (Next 10 Yrs)

At the current price of $261.77, the market is assuming the business will compound Free Cash Flow at 5.7% per year for the next decade with a 9% hurdle rate.

Value Investor Verdict

✓ Low market hurdle: Easy for a wide-moat compounder to beat.

Autonomous Thesis Underwriting

Surveil IQV with Mathematical Margin of Safety Rules

Set non-negotiable floor rules for IQVIA Holdings, Inc.. If a newly filed quarterly 10-Q breaks your ROIC floor, operating margin boundary, or balance sheet leverage rules, receive an autonomous breach audit within 15 minutes.

Buffett Quality

ROIC > 15% • Margin > 15% • D/E < 0.5x

Margin Floor Guard

Current Margin 13% • Floor > 10%

Solvency Guard

Altman-Z > 2.6 • Current Ratio > 1.5x

Track IQV & Set Alerts Browse S&P 500 Coverage

Frequently Asked Questions: IQVIA Holdings, Inc. (IQV) Intrinsic Valuation

Audited fundamentals, DCF intrinsic value sensitivity, and thesis break detection parameters for IQVIA Holdings, Inc..

Based on institutional multi-stage Discounted Cash Flow (DCF) modeling on audited SEC cash flows, IQVIA Holdings, Inc. has an estimated DCF intrinsic fair value of $175.09 per share compared to its current market price of $261.77. This represents an estimated 49.5% premium over fair value. Additionally, its classic Benjamin Graham Number stands at $82.30.